IL6 and macrophage activation syndrome: Cytokine blockade of IL-1 and IL-6 with anakinra, canakinumab, and tocilizumab are used routinely in treatment of sHLH/MAS [21]; and more recently, cytokine directed therapies have been approved and used effectively in the treatment of severe COVID-19, further increasing evidence of a hyperinflammatory component during high disease activity.